Project Details
Description
4014: A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/18 → 12/31/21 |
Funding
- TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.